hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06270277, orgStudyIdInfo id: 30.01.2024-4272, briefTitle: Evaluation of Quality of Life and Psychosocial Status in Children With Inflammatory Bowel Disease, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-02-14, primaryCompletionDateStruct date: 2024-02-20, completionDateStruct date: 2024-02-21, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Sisli Hamidiye Etfal Training and Research Hospital, class: OTHER, descriptionModule briefSummary: Inflammatory bowel disease (IBD) is a chronic condition that affects the psychosocial status and physical activities of children and their parents in many ways. Our study aimed to investigate the variability of disease-related quality of life and behavioral and emotional adjustment issues compared to a healthy control group among adolescents and their families diagnosed with IBD. Children with IBD and the healthy control group, as well as the parents of both groups, will administered the Pediatric Quality of Life Inventory (PedsQL) and Strengths and Difficulties Questionnaire (SDQ). The PedsQL is a scale used to assess physical and psychosocial functioning based on the individual's own experiences, commonly employed in clinical trials and quality improvement initiatives. The scale evaluates physical activity status and psychosocial functioning through questions related to emotional, social, and school-related issues., conditionsModule conditions: Inflammatory Bowel Diseases, conditions: Psychosocial Impairment, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Adolescents with Inflammatory bowel diseases and healthy control group in same age will be administered Pediatric Quality of Life Inventory (PedsQL) and Strengths and Difficulties Questionnaire (SDQ)., primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 159, type: ACTUAL, armsInterventionsModule interventions name: Pediatric Quality of Life Inventory (PedsQL), interventions name: Strengths and Difficulties Questionnaire (SDQ), outcomesModule primaryOutcomes measure: Pediatric Quality of Life Inventory (PedsQL) score, primaryOutcomes measure: Strengths and Difficulties Questionnaire (SDQ), eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Sisli Hamidiye Etfal Research and Training Hospital, city: Istanbul, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06270264, orgStudyIdInfo id: 111-2023, briefTitle: Nociception Monitoring in Intensive Care, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-08-01, primaryCompletionDateStruct date: 2023-12-15, completionDateStruct date: 2024-01-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Haseki Training and Research Hospital, class: OTHER, descriptionModule briefSummary: Precisely, pain in the ICU is a multidimensional problem with a multivariate of reasons. Still, it would be simpler to manage it in unconscious palliative patients with less source of pain, but only if we can detect it practically with the help of nociception monitors. Using five parameters, nociception level index (NOL) monitoring (Medasense) is differentiated from its alternatives. Other than pain detection, this monitoring can titrate analgesic administration. This study investigates the validity of a new nociception monitoring tool, the nociception level index, and its practical impact on providing adequate analgesia in palliative patients in intensive care., conditionsModule conditions: Unconscious State, conditions: Pressure Ulcer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: randomized, prospective and controlled, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: the Nociception level index monitoring, outcomesModule primaryOutcomes measure: total fentanyl consumption, secondaryOutcomes measure: systolic blood pressure, secondaryOutcomes measure: heart rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Haseki Training and Research Hospital, city: Istanbul, state: Sultangazi, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06270225, orgStudyIdInfo id: SSGJ-613-PGF-II-01, briefTitle: A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment., conditionsModule conditions: Gout Arthritis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg, interventions name: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, interventions name: Colchicine 0.5 mg, outcomesModule primaryOutcomes measure: Numbers of acute gout flares, secondaryOutcomes measure: Numbers of acute gout flares, secondaryOutcomes measure: Proportions of subjects with at least 1 acute gout flare, secondaryOutcomes measure: Proportions of subjects with at least 1 acute gout flare, secondaryOutcomes measure: Time from randomization to first acute flare., secondaryOutcomes measure: Duration of acute gout flares., secondaryOutcomes measure: Duration of acute gout flares., secondaryOutcomes measure: Subject's overall assessment of response to treatment, secondaryOutcomes measure: Investigator's overall assessment of response to treatment, secondaryOutcomes measure: 36-item Short Form Survey (SF-36), secondaryOutcomes measure: Adverse events (AE), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Huashan Hospital Fudan University-Rheumatology, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200040, country: China, contacts name: Hejian Zou, MD, role: CONTACT, phone: +86 13311881366, email: hjzou@fudan.edu.cn, contacts name: Hejian Zou, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06270173, orgStudyIdInfo id: TWM-C-2202, briefTitle: Post-Market Study of The Tripod-Fix Vertebral Body Augmentation System in Osteoporotic Vertebral Compression Fractures, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-16, primaryCompletionDateStruct date: 2025-07-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Wiltrom Co., Ltd., class: INDUSTRY, collaborators name: Maxis Medical GmbH, descriptionModule briefSummary: The objective of this Post-Market Clinical Follow-Up Study is to evaluate the safety and performance of the Tripod-Fix in the treatment of vertebral compression fractures (VCF) resulting from osteoporosis., conditionsModule conditions: Osteoporotic Vertebral Compression Fractures, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix), outcomesModule primaryOutcomes measure: Proportion of participants with study success, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Klinikum Friedrichshafen, status: NOT_YET_RECRUITING, city: Friedrichshafen, state: Baden-Württemberg, zip: 88048, country: Germany, contacts name: Ludwig Oberkircher, Prof Dr med, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 47.65689, lon: 9.47554, locations facility: University Hospital Mannheim, status: NOT_YET_RECRUITING, city: Mannheim, state: Baden-Württemberg, zip: 68167, country: Germany, contacts name: Frederic Bludau, PD Dr med, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 49.4891, lon: 8.46694, locations facility: Johann Wolfgang Goethe University Frankfurt/Main, status: NOT_YET_RECRUITING, city: Frankfurt am Main, state: Hesse, zip: 60596, country: Germany, contacts name: Thomas Vogl, Prof Dr med, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 50.11552, lon: 8.68417, locations facility: Krankenaus Mechernich, status: RECRUITING, city: Mechernich, state: North-Rhine-Westphalia, zip: 53894, country: Germany, contacts name: Robert Pflugmacher, Prof Dr med, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 50.59304, lon: 6.65224, hasResults: False
protocolSection identificationModule nctId: NCT06270147, orgStudyIdInfo id: 16935, briefTitle: Timing of TAP Blocks in Bariatric Surgery, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-04, primaryCompletionDateStruct date: 2024-06-28, completionDateStruct date: 2024-06-28, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: McMaster University, class: OTHER, descriptionModule briefSummary: This clinical trial aims to determine the optimal timing for administering a Transversus Abdominis Plane (TAP) block in bariatric surgery, specifically investigating whether initiating TAP blocks at the beginning of surgery is more beneficial than at the end, which is the current practice. The study targets obese patients undergoing bariatric surgery, with a focus on reducing postoperative pain and opioid use. Key outcomes include recovery duration, pain levels, opioid consumption, and respiratory function. Successful results could establish early TAP block initiation as a standard practice, offering faster recovery, decreased opioid reliance, and reduced healthcare costs., conditionsModule conditions: Opioid Use, conditions: Pain, Postoperative, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Bupivacaine-epinephrine, outcomesModule primaryOutcomes measure: Opioid Consumption, secondaryOutcomes measure: Length of Stay, secondaryOutcomes measure: Anesthesia requirements, secondaryOutcomes measure: Sedation requirements, secondaryOutcomes measure: Nausea and vomiting, secondaryOutcomes measure: Respiratory Status, secondaryOutcomes measure: Opioid consumption, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06270134, orgStudyIdInfo id: 14410, briefTitle: Dial-Bicarb Trial: Effects of a Lower vs. Higher Concentration of Dialysate Bicarbonate, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-01, primaryCompletionDateStruct date: 2029-01, completionDateStruct date: 2029-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: McMaster University, class: OTHER, collaborators name: Canadian Institutes of Health Research (CIHR), descriptionModule briefSummary: This is a pragmatic, two-arm, parallel-group, open-label, individual-randomized, superiority trial that will be conducted in hemodialysis units across Ontario. Patients at each dialysis unit will be randomly allocated into one of two study arms in a 1:1 ratio to receive a dialysate bicarbonate concentration of either 32 or 38 mmol/L. The intervention will be embedded into routine care and delivered by hemodialysis unit personnel., conditionsModule conditions: Hemolysis, conditions: Renal Failure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This is a pragmatic, two-arm, parallel-group, open-label, individual-randomized, superiority trial that will be conducted in hemodialysis units across Ontario. Patients at each dialysis unit will be randomly allocated into one of two study arms in a 1:1 ratio to receive a dialysate bicarbonate concentration of either 32 or 38 mmol/L., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 5000, type: ESTIMATED, armsInterventionsModule interventions name: Bicarbonate, outcomesModule primaryOutcomes measure: Non-elective hospitalizations or mortality, secondaryOutcomes measure: Hospitalizations and fractures, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06270095, orgStudyIdInfo id: C21-57, briefTitle: " Fume Events in Air Flights: Consequences on Cabin Air Quality and on Aircrews Health of a French Fleet of Aircraft", acronym: AVISAN, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Institut National de la Santé Et de la Recherche Médicale, France, class: OTHER_GOV, collaborators name: Université Paris Cité, collaborators name: National Agency for Sanitary Safety of the Food of the Environment and Labor, descriptionModule briefSummary: The subject of the study focuses on commercial aircraft's cabins air quality, under conditions of both fume events and non-fume events. It also delves into the immediate and delayed repercussions of these events on the health of aviation crew members. The expological facet of this study is directed at the detection and quantification of organophosphorus compounds originating from engine oils. The epidemiological facet is geared towards the identification of potential neurological consequences., conditionsModule conditions: Neurologic Symptoms, conditions: Neurologic Disorder, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1200, type: ESTIMATED, armsInterventionsModule interventions name: Neurocognitive, neuromuscular and neurosensitive tests., outcomesModule primaryOutcomes measure: Neurocognitive self-assessment tests on digital tablet - CANTAB test battery: Paired Associates Learning, primaryOutcomes measure: Neurocognitive self-assessment tests on digital tablet - CANTAB test battery: Rapid Visual Information Processing, primaryOutcomes measure: Neurocognitive self-assessment tests on digital tablet - CANTAB test battery: One Touch Stockings of Cambridge, primaryOutcomes measure: Neurosensitive test to explore superficial and deep sensitivity deficits in peripheral neuropathies, primaryOutcomes measure: Neuromuscular test to evaluate muscle strength assessment, primaryOutcomes measure: Symptoms experienced during the flight or within 72 hours after the flight, duration of symptoms, symptoms experienced previously outside the flight, secondaryOutcomes measure: Characteristics of plane and fume event and possible causes of fume event, secondaryOutcomes measure: Measurement of organophosphorus and carbon monoxide in cabin air using an air sampler and a piston syringe., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 67 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06270069, orgStudyIdInfo id: 2024-001, briefTitle: Responsiveness and Minimal Important Change of Two Measures of Pain Intensity in People With Low Back Pain, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-02-28, completionDateStruct date: 2025-02-28, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: International Institute of Behavioral Medicines, class: OTHER, descriptionModule briefSummary: This is an observational study aimed at evaluating the responsiveness and minimal important change of two measures of pain intensity in people with low back pain. It consists of a battery of self-administered questionnaires which will be given to individuals with low back pain to complete before and after a rehabilitation treatment. Relationships among the different outcome measures will be also evaluated., conditionsModule conditions: Low Back Pain, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Excercise-based therapy, outcomesModule primaryOutcomes measure: NRS, primaryOutcomes measure: Gauge of pain, secondaryOutcomes measure: ODI, secondaryOutcomes measure: PCS, secondaryOutcomes measure: TSK, secondaryOutcomes measure: PSEQ, secondaryOutcomes measure: GPE, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06270056, orgStudyIdInfo id: 1058, briefTitle: Evaluation of Telemedicine Medical Abortion Service in Ecuador, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-02, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Gynuity Health Projects, class: OTHER, descriptionModule briefSummary: This research seeks to demonstrate that a telemedicine model for the provision of legal abortion services in Ecuador is safe, feasible and acceptable to users requesting a medication abortion and who are less than 12 weeks pregnant., conditionsModule conditions: Pregnancy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Misoprostol, outcomesModule primaryOutcomes measure: Adverse events (safety), secondaryOutcomes measure: Feasibility of telemedicine service, secondaryOutcomes measure: Acceptability of telemedicine service, eligibilityModule sex: FEMALE, minimumAge: 15 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: El Comité de Derechos Sexuales y Reproductivos de Ecuador (CODESER), city: Ambato, country: Ecuador, contacts name: Maria Fernanda Morales, role: CONTACT, phone: 593 998220369, email: mafer_moca@yahoo.es, geoPoint lat: -1.24908, lon: -78.61675, locations facility: Cemoplaf, city: Quito, country: Ecuador, contacts name: Gabriela Rivera, role: CONTACT, phone: 593 995512828, email: gabyrivera2398@hotmail.com, geoPoint lat: -0.22985, lon: -78.52495, locations facility: Federación Nacional de Obstetrices y Obstetras del Ecuador (FENOE), city: Quito, country: Ecuador, contacts name: Paola Tito, role: CONTACT, phone: 593 22951737, email: paojaime@hotmail.es, geoPoint lat: -0.22985, lon: -78.52495, hasResults: False
protocolSection identificationModule nctId: NCT06270043, orgStudyIdInfo id: 809622, briefTitle: Focal Therapy for Localized Prostate Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2034-02-01, completionDateStruct date: 2034-02-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: University of California, San Diego, class: OTHER, descriptionModule briefSummary: This prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. The goal of which is to improve patient care., conditionsModule conditions: Prostate Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: Focal Therapy, outcomesModule primaryOutcomes measure: Oncological Response, secondaryOutcomes measure: Erectile Dysfunction, secondaryOutcomes measure: Incontinence, secondaryOutcomes measure: Prostate cancer recurrence. Patients will be monitored with a Prostate Specific Antigen (PSA) every 6 months until 10 years from the intervention. Patients with a rising PSA will receive a prostate biopsy to determine if they have a recurrence., eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of California, San Diego, status: RECRUITING, city: La Jolla, state: California, zip: 92121, country: United States, contacts name: Juan Javier-DesLoges, MD, role: CONTACT, phone: 858-657-8786, email: jjavierdesloges@health.ucsd.edu, geoPoint lat: 32.84727, lon: -117.2742, hasResults: False
protocolSection identificationModule nctId: NCT06270030, orgStudyIdInfo id: JX07002, secondaryIdInfos id: CTR20240460, type: OTHER, domain: China Center for Drug Evaluation (CDE), NMPA, briefTitle: Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-03-04, primaryCompletionDateStruct date: 2024-04-10, completionDateStruct date: 2024-04-10, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Ji Xing Pharmaceuticals (Shanghai) Co., Ltd., class: INDUSTRY, collaborators name: LENZ Therapeutics, Inc, descriptionModule briefSummary: Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Chinese Healthy Adult Subjects with Presbyopia, conditionsModule conditions: Presbyopia, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 21, type: ACTUAL, armsInterventionsModule interventions name: LNZ101 (Aceclidine /Brimonidine) ophthalmic solution, interventions name: LNZ100 (Aceclidine) ophthalmic solution, interventions name: Placebo (Vehicle) ophthalmic solution, outcomesModule primaryOutcomes measure: Cmax, primaryOutcomes measure: Tmax, primaryOutcomes measure: AUC0-t, primaryOutcomes measure: AUC0-∞, primaryOutcomes measure: T1/2, primaryOutcomes measure: Safety: adverse event reporting, eligibilityModule sex: ALL, minimumAge: 45 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai General Hospital, city: Shanghai, state: Shanghai, zip: 200080, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False